Zeranovia(TM) Weight Loss Product Shows Promising Results in Dosage Trial
BioAdaptives Inc. (OTC: BDPT) has announced successful completion of dosage trials for its weight loss product Zeranovia™. The trial demonstrated significant results, with participants experiencing weight loss of 5-7 pounds per week with minimal side effects.
Key findings include consistent weight loss across participants, with the main side effect being mild gastrointestinal discomfort, manageable through increased water intake or dosage adjustments. All trial subjects requested to proceed to the next phase, demonstrating high satisfaction levels.
Based on these promising results, BioAdaptives is proceeding with dosage adjustments for the next stage of clinical trials, aiming to address the global need for effective and safe weight loss solutions.
BioAdaptives Inc. (OTC: BDPT) ha annunciato il completamento con successo dei trial di dosaggio per il suo prodotto per la perdita di peso Zeranovia™. Il trial ha dimostrato risultati significativi, con i partecipanti che hanno sperimentato una perdita di peso di 5-7 libbre a settimana con effetti collaterali minimi.
I risultati chiave includono una perdita di peso costante tra i partecipanti, con l'unico effetto collaterale principale che è un lieve disagio gastrointestinale, gestibile attraverso un aumento dell'assunzione di acqua o aggiustamenti del dosaggio. Tutti i soggetti del trial hanno richiesto di procedere alla fase successiva, dimostrando alti livelli di soddisfazione.
Basandosi su questi risultati promettenti, BioAdaptives sta procedendo con gli aggiustamenti del dosaggio per la prossima fase dei trial clinici, mirando a rispondere all'esigenza globale di soluzioni per la perdita di peso efficaci e sicure.
BioAdaptives Inc. (OTC: BDPT) ha anunciado la finalización exitosa de los ensayos de dosificación para su producto de pérdida de peso Zeranovia™. El ensayo demostró resultados significativos, con los participantes experimentando una pérdida de peso de 5-7 libras por semana con efectos secundarios mínimos.
Los hallazgos clave incluyen una pérdida de peso constante entre los participantes, siendo el principal efecto secundario un leve malestar gastrointestinal, manejable a través del aumento de la ingesta de agua o ajustes en la dosificación. Todos los sujetos del ensayo solicitaron avanzar a la siguiente fase, demostrando altos niveles de satisfacción.
Basándose en estos resultados prometedores, BioAdaptives está procediendo con ajustes de dosificación para la próxima etapa de ensayos clínicos, con el objetivo de abordar la necesidad global de soluciones efectivas y seguras para la pérdida de peso.
BioAdaptives Inc. (OTC: BDPT)는 체중 감량 제품 Zeranovia™의 용량 시험이 성공적으로 완료되었음을 발표했습니다. 시험 결과, 참가자들은 주당 5-7파운드의 체중 감량을 경험했으며 부작용은 최소한이었습니다.
주요 발견 사항으로는 참가자들 간의 일관된 체중 감량이 있었으며, 주요 부작용은 경미한 위장 불편감으로, 이는 수분 섭취 증가 또는 용량 조정을 통해 관리할 수 있었습니다. 모든 시험 참가자들은 다음 단계로 진행하기를 요청하며 높은 만족도를 보여주었습니다.
이러한 유망한 결과를 바탕으로 BioAdaptives는 다음 단계의 임상 시험을 위한 용량 조정을 진행하고 있으며, 효과적이고 안전한 체중 감량 솔루션에 대한 글로벌 수요를 충족하고자 하고 있습니다.
BioAdaptives Inc. (OTC: BDPT) a annoncé l'achèvement réussi des essais de dosage pour son produit de perte de poids Zeranovia™. L'essai a montré des résultats significatifs, les participants ayant perdu entre 5 et 7 livres par semaine avec des effets secondaires minimes.
Les résultats clés comprennent une perte de poids constante chez les participants, l'effet secondaire principal étant un léger inconfort gastro-intestinal, gérable par une augmentation de l'apport en eau ou des ajustements de dosage. Tous les sujets de l'essai ont demandé à passer à la phase suivante, montrant des niveaux de satisfaction élevés.
Sur la base de ces résultats prometteurs, BioAdaptives procède à des ajustements de dosage pour la prochaine étape des essais cliniques, visant à répondre au besoin mondial de solutions efficaces et sûres pour la perte de poids.
BioAdaptives Inc. (OTC: BDPT) hat den erfolgreichen Abschluss der Dosierungsstudien für sein Gewichtsverlustprodukt Zeranovia™ bekannt gegeben. Die Studie zeigte signifikante Ergebnisse, wobei die Teilnehmer einen Gewichtsverlust von 5-7 Pfund pro Woche mit minimalen Nebenwirkungen erlebten.
Wesentliche Ergebnisse umfassen einen konsistenten Gewichtsverlust bei den Teilnehmern, wobei die Hauptnebenwirkung ein mildes gastrointestinales Unbehagen war, das durch erhöhten Wasserverbrauch oder Anpassungen der Dosierung verwaltet werden konnte. Alle Studienteilnehmer baten darum, zur nächsten Phase überzugehen, was ein hohes Maß an Zufriedenheit zeigt.
Basierend auf diesen vielversprechenden Ergebnissen geht BioAdaptives mit Anpassungen der Dosierung in die nächste Phase der klinischen Studien, um dem globalen Bedarf an effektiven und sicheren Gewichtsverlustlösungen gerecht zu werden.
- Strong weight loss results: 5-7 pounds per week in trial participants
- High participant satisfaction with all subjects requesting to continue to next phase
- Minimal and manageable side effects reported
- Product still in early trial phases, requiring additional clinical testing
- Presence of gastrointestinal side effects, though mild
LAS VEGAS, March 13, 2025 (GLOBE NEWSWIRE) -- via IBN -- BioAdaptives Inc. (OTC: BDPT) today announced the successful completion of dosage trials for its innovative weight loss product, Zeranovia™. The trial demonstrated significant weight loss results with minimal side effects, marking a crucial product development milestone.
During the trial, participants experienced weight loss ranging from 5 to 7 pounds per week. Side effects were minimal, with the most common being mild gastrointestinal discomfort, which was easily managed by increasing water intake or adjusting the product dosage.
"We are thrilled with the results of this dosage trial," said James Keener, CEO. "The consistent weight loss across participants, coupled with the manageable side effect profile, indicates that Zeranovia™ has the potential to be a game-changer in the weight loss market."
Key findings from the dosage trial include:
- Consistent weight loss across participants
- Minimal side effects, easily managed with simple adjustments
- High participant satisfaction, with all trial subjects requesting to proceed to the next phase
Based on these promising results, BioAdaptives is moving forward with dosage adjustments for the next stage of clinical trials. The company is optimistic about the product's potential to address the growing global need for effective and safe weight loss solutions.
"The enthusiasm from our trial participants is incredibly encouraging," added Keener. "Their eagerness to continue with the next phase of testing speaks volumes about the product's effectiveness and tolerability."
BioAdaptives is committed to developing innovative solutions for weight management. The company anticipates releasing further updates as the clinical trial progresses.
About BioAdaptives, Inc.
BioAdaptives, Inc. (OTC: BDPT) is a leading innovator in the health and wellness industry. We are dedicated to developing and marketing nutraceutical and wellness products that harness the power of natural ingredients and cutting-edge science. Our mission is to improve the quality of life for our customers by offering products that support optimal health and vitality.
For more information, please visit our website at www.bioadaptives.com.
Contact Information:
BioAdaptives, Inc.
Emily Harrison
IR Coordinator
(702)-659-8829
info@bioadaptives.com
2620 Regatta Dr, Suite 102
Las Vegas, NV 89128
Forward-Looking Statements: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, among other things, statements regarding expected growth, potential benefits of the company's products, and future business opportunities. These statements involve risks, uncertainties, and other factors that may cause actual results or developments to differ materially from those expressed or implied.
Wire Service Contact:
IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
Editor@InvestorBrandNetwork.com
FAQ
What were the weight loss results from BDPTD's Zeranovia trial?
What side effects were reported in BioAdaptives' Zeranovia weight loss trial?
How did participants respond to BDPTD's Zeranovia weight loss product?
What is the next step for BioAdaptives' Zeranovia after the successful dosage trial?
